• Profile
Close

Improved survival among hospitalized patients with COVID-19 treated with remdesivir and dexamethasone. A nationwide population-based cohort study

Clinical Infectious Diseases Jun 14, 2021

Benfield T, Bodilsen J, Brieghel C, et al. - In this study, the efficacy of standard of care (SOC) alone vs SOC plus remdesivir and dexamethasone was compared. Researchers enrolled two population-based nationwide cohorts of individuals hospitalized with COVID-19 during February through December 2020. They compared death within 30 days and need of mechanical ventilation (MV) by inverse probability of treatment weighted logistic regression analysis and shown as odds ratio with 95% confidence interval. This study’s findings demonstrate that treatment of moderate to severe COVID-19 during June through December that included remdesivir and dexamethasone was correlated with decreased 30-day mortality and need of MV in comparison with treatment in February through May.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay